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Abstract
Background: The effect of aggressive medical therapy on quantitative coronary plaque burden is not generally
known, especially in ethnic Chinese.
Aims: We reasoned that Cardiac CT could conveniently quantify early coronary atherosclerosis in our patient
population, and hypothesized that serial observation could differentiate the efficacy of aggressive medical therapy
regarding progression and regression of the atherosclerotic process, as well as evaluating the additional impact of
life-style modification and the relative effects of the application of statin therapy.
Methods: We employed a standardized Cardiac CT protocol to serially scan 113 westernized Hong Kong Chinese
individuals (64 men and 49 women) with Chest Pain and positive coronary risk factors. In all cases included for this
serial investigation, subsequent evaluation showed no significantly-obstructive coronary disease by functional
studies and angiography. After stringent risk factor modification, including aggressive statin therapy to achieve
LDL-cholesterol lowering conforming to N.C.E.P. ATP III guidelines, serial CT scans were performed 1-12 years apart
for changes in coronary artery calcification (CAC), using the Agatston Score (AS) for quantification.
Results: At baseline, the mean AS was 1413.6 for males (mean age 54.4 years) and 2293.3 for females (mean age
62.4 years). The average increase of AS in the entire study population was 24% per year, contrasting with 16.4%
per year on strict risk factor modification plus statin therapy, as opposed to 33.2% per year for historical control
patients (p < 0.001). Additionally, 20.4% of the 113 patients demonstrated decreasing calcium scores. Medical
therapy also yielded a remarkably low adverse event rate during the follow-up period — 2 deaths, 2 strokes and
only 1 case requiring PCI.
Conclusions: This study revealed that aggressive medical therapy can positively influence coronary plaque aiding
in serial regression of calcium scores.
Background
It is not generally known what happens to the coronary
calcium score when patients are subjected to aggressive
medical therapy on long-term follow-up. Furthermore,
there is a paucity of information on the prevalence of
coronary artery disease in some groups of individuals,
especially certain ethnic groups such as the Chinese.
Although there are data available on Chinese patients
[1-5], such data usually touch on a few selected para-
meters and rarely focus on the prevalence aspect of cor-
onary artery disease in the Chinese.
After CT cardiac imaging of the coronary system
became established as a means of detecting underlying
atherosclerosis [6], serial scans were performed in some
studies to follow progress of disease in certain special
groups of individuals [7,8].
The MESA study [9] observed that lipid levels were
related to baseline coronary artery calcification (CAC)
burden but not to CAC progression. Similarly, DA
Anand et al. [10] found that statins were unable to pre-
vent CAC progression. On the other hand, P Raggi et al.
[11] found that CAC progression in diabetic subjects
was greater in the absence of statins. ND Wong et al.
[12] then opined that only HDL Cholesterol rather than
LDL Cholesterol was related to CAC progression.
Past and present uncertainties on the causes of CAC
progression are a natural impetus for further research
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into this subject. Our thoughts on this area led us to
reason that Cardiac CT could be applied effectively to
quantify the burden of coronary atherosclerosis, with
the hypothesis that performing serial scans could shed
light on the efficacy of aggressive medical therapy and
hence improve management of CAD, particularly in
assessing possible factors that govern progression and
regression of the atherosclerotic process, secondly in
determining any difference between giving statins alone
and administering statins together with life-style modifi-
cation, and thirdly in evaluating whether type and dose
of statins would make a difference. Furthermore, since
the development of atherosclerotic plaque literally takes
decades, a longer term follow-up than had been applied
in prior studies was felt to provide a better comprehen-
sion of long-term consequences to therapeutic
interventions.
113 patients with non-critical coronary disease consti-
tuted the population for this long-term follow-up study.
This group, which comprised 64 men and 49 women,
had two or more consecutive CT coronary calcium
scans at least 12 months apart. Their response to
aggressive non-invasive, medical therapy is described
below.
Methods
Patient Demographics and Entry Criteria
We studied a group of westernized ethnic Chinese
urban inhabitants with positive risk factors and chest
pain. At entry, patients were interviewed and gave
informed consent. Those who had been undergoing a
previous course of treatment for coronary artery disease
were excluded, as were patients who had unstable chest
symptoms. Only those presenting with chest symptoms
for the first time and who had never had a prior cardiac
CT examination were accepted into the study. They
firstly received a non-contrast CT scan for calcified cor-
onary artery plaque determination. Cases with a positive
scan then underwent traditional testing for stratification
of cardiac risk. Those patients found to be at high risk
and who had significant coronary stenosis on subse-
quent coronary angiography proceeded to revasculariza-
tion and were not included in this investigation. The
remaining subjects were either free of coronary athero-
matous plaque or had non-critical coronary artery dis-
ease. These patients were then selected for the study.
This group eventually comprised 64 men aged between
28 and 83 years (mean age 54.4 years) and 49 women
aged between 36 and 86 years (mean age 62.4 years)
[Figure 1].
The estimated pretest likelihood of significant coron-
ary artery disease [13] of this study group is given in
Table 1 (< 50% likelihood in 32 out of 113 patients (=
28.3%), 50 - 80% likelihood in 37 out of 113 patients (=
32.7%), and > 80% likelihood in 26 out of 113 patients
(= 23%)).
Protocol
All patients with chest pain and positive coronary risk
factors meeting the above-mentioned criteria for
inclusion received a blood test to determine their bio-
chemical Risk Profile (including Total Cholesterol,
HDL-Cholesterol, LDL-Cholesterol, VLDL-Cholesterol,
Triglycerides, Glucose, Uric Acid). As mentioned, they
also had a non-contrast CT of their coronary system.
Patients who had positive calcium scores of 400 Agat-
ston score or above (indicating severe disease) then
underwent a stress test for stratification of cardiac risk.
Eventually 20 patients with a heavy calcium score and a
positive stress test were catheterized for their intralum-
inal status. 19 patients with significant coronary stenosis
on coronary angiography proceeded to revascularization
and were excluded. The 113 remaining risk factor-bear-
ing symptomatic patients (with either no coronary pla-
que burden or having non-critical coronary disease)
then constituted the subjects for this long-term follow-
up study.
Patients started the study in 1990-1992, and were
rescanned as late as 2002, with the time between scans
averaging 10 ± 1.5 years.
Instrumentation
All patients underwent electron beam Computerized
Tomography of their coronary arteries by a standard
protocol [14]. The cardiac CT studies (both at baseline
and follow-up) were performed with an Imatron C-100
and subsequently a C-150 electron beam computed
tomographic scanner (Imatron, South San Francisco,
California) in high-resolution volume mode using a 100-
ms exposure time as previously described [15]. As the
study progressed, it became apparent that electrocardio-
graphic triggering was desirable to enable each image to
be obtained during the quiet time of the cardiac cycle,
which eventually corresponded to 40% of the RR interval
[15,16], while scans were initially non-gated during the
early 5 years of the study (comprising about one-third
of the total patient population). Proximal coronary
artery visualization was obtained, and 30 or more conse-
cutive images were obtained at 3-mm intervals. Total
radiation exposure using this technique was <1 mSv per
participant per session (which low value was achievable
because of the extremely rapid prospective acquisition
of data by EBCT, and which is superior even to later
generations of MDCT scanners by not involving any
mechanically-movable parts in its hardware that could
slow down scanner activity to require multiple
sequences with protracted irradiation). Participants were
included in this study only if complete data were
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available from the scans, without mis-registration of
slices due to motion artifacts, respiration, or poor elec-
trocardiographic triggering.
Image Analysis
The site and extent of calcification of each diseased ves-
sel was documented and stored for future re-analysis/
comparison. In the acquired images, calcification was
defined as a plaque of at least 3 contiguous pixels (area
1.03 mm2) with a density of >130 Hounsfield units. The
amount of calcium was quantified using a lesion score.
This score, as described by Agatston et al. [14], was cal-
culated by multiplying the lesion area by a coefficient
based on the peak density within that plaque. The total
Agatston Score of the participant was determined by
summing the scores obtained for each lesion. The voxel
size on cardiac CT scans obtained with a 3-mm section
thickness and a typical field of view of 30 cm2 (pixel
size = 0.586 mm) corresponds to 0.586 × 0.586 × 3 =
1.03 mm3. The original voxel was divided into smaller
Figure 1 Flow Chart showing how patients were selected for entering the study.
Table 1 Cases presenting with Chest Pain to compute pretest likelihood of CAD
Atypical Chest Pain Typical Chest Pain
Age Men Women Men Women
20 - 29 1 case 0 0 0
30 - 39 21.8% × 5 cases 4.2% × 1 case 69.7% × 1 case 25.8% × 0
40 - 49 46.1% × 13 cases 13.3% × 2 cases 87.3% × 8 cases 55.2% × 0
50 - 59 58.9% × 10 cases 32.4% × 11 cases 92.0% × 6 cases 79.4% × 5 cases
60 - 69 67.1% × 5 cases 54.4% × 11 cases 94.3% × 5 cases 90.6% × 7 cases
70 - 79 5 cases 6 cases 4 cases 5 cases
80 - 89 1 case 1 case 0 0
Overall < 50% Likelihood:
32/113 (= 28.3% of cases)
50 – 80% Likelihood:
37/113 (= 32.7% of cases)
> 80% Likelihood:
26/113 (= 23% of cases)
Goh et al. Cardiovascular Ultrasound 2010, 8:5
http://www.cardiovascularultrasound.com/content/8/1/5
Page 3 of 11
voxels each of whose size was 0.201 mm3 with the tech-
nique of isotropic interpolation for measuring a more
precise volume [17,18]. All voxels with a value greater
than 130 Hounsfield units were defined as a calcified
lesion. A total coronary artery score by the Agatston
method was determined by summing individual lesion
scores from each of 4 anatomic sites (left main, left
anterior descending, circumflex, and right coronary
arteries). A single experienced investigator, blinded to
clinical status of the participant and temporal relation of
the scans, interpreted all studies on a commercially
available software package (AccuImage Diagnostics
Corp., South San Francisco, California).
Intra- and Inter-observer variability in CT calcium
scoring has been reported [19]. Since only one investiga-
tor read all the scans, this eliminated inter-observer
variability. Intra-observer variability has been found to
be low [19], the correlation being on the order of 0.99.
Treatment
The number of risk factors for a participant was calcu-
lated based on the National Cholesterol Education Pro-
gram guidelines [20-22]. Risk Factors included: current
cigarette smoking, history of premature coronary disease
in a first-degree relative, diabetes mellitus, hypertension,
and hypercholesterolemia. Cigarette smoking was
defined as use of >10 cigarettes/day. Participants using
insulin or oral hypoglycemic agents were classified as
diabetic. Hypertension was defined by use of antihyper-
tensive medication or known and untreated hyperten-
sion, and hypercholesterolemia was similarly defined by
use of cholesterol-lowering medication or known but
untreated high cholesterol (total>6.3 mmol/L).
When calcified plaques were demonstrated, individuals
would be counseled about possible dangers (such as
development of coronary events), and advised on life-
style modification. Typically patients would be advised
to start a low cholesterol diet and asked to do slow-
paced exercises for at least 1 hour each day, according
to N.C.E.P. guidelines, starting with the ATP I, proceed-
ing on to the ATP II and finally the ATP III guidelines
when each new set of guidelines became available
[20-22]. Drug therapy for hypercholesterolemia was only
started after obtaining lipid and body-organ biochemis-
try as baseline parameters to ensure tolerability to drug
treatment. Statins were only started when patients met
the criteria for such treatment with respect to ATP
guidelines, while calcium scores were not relied upon in
committing patients to statin therapy. The dosage of
statins used started from the lowest recommended dose
for each choice of statin and was individualized for each
patient to enable him/her to achieve LDL cholesterol
levels as per the NCEP guidelines operating at the time.
The maximal dose of each choice of statin is listed in
Table 2. Subsequently, patients were asked to return for
regular clinical follow-up by one of the authors as well
as to report any new developments even before their
next due appointment.
Statistical analysis
With each subsequent review, patients’ history and clini-
cal/laboratory findings were recorded. In particular, each
patient’s life-style status was re-assessed by going
though a check-list of parameters to track patients’ pro-
gress. The degree of progression was calculated as the
annualized percent difference between the 2 scans, and
comparisons of mean relative changes in the calcium
score were made with the student’s T test. A rising
trend in the serial calcium score was defined as either
progressive elevation in score value or at least a rise in
score between two consecutive scans, while a decreasing
trend was the opposite. A 2-sample z test was used to
document the significance of the difference between
groups in the proportion of participants with any given
risk factor or intervention. Hypertension, tobacco use,
diabetes, age, gender, family history of premature heart
disease, number of risk factors, hypercholesterolemia
and the utilization of statin therapy were evaluated as
independent variables.
Results
Demographics/Calcium Score Range (at study entry)
Tables 3 and 4 show the demographics and range of cal-
cium scores of subjects in the study at baseline entry.
The mean calcium score was 1413.6 for Males and
2293.3 for Females (females being nearly a decade older
than males).
Progress of Calcium Score Results
All patients were consistently kept on aggressive statin
therapy to keep their LDL-Cholesterol level according to
N.C.E.P. guidelines operative at the time (<100 mg/dl or
<2.63 mmol/L). All medical problems (e.g. hypertension,
diabetes) were checked to ensure persistent optimal
control (optimal blood pressure was defined as < 120-
130/70-80; optimal fasting blood sugar was defined as <
6.1 mmol/L). Finally, all patients were interviewed at
each clinical follow-up session regarding the complete-
ness of their life-style modification, with cross-referen-
cing made with family members to ascertain accuracy.
The study revealed the progress of patients’ calcium
scores proceeded along several different courses.
Progression of CAC scores
A RISING TREND [Figure 2] was seen in 70 patients
whether they were on stand-alone statin therapy or on
Life-style Modification with statin therapy. Among these
70 patients, the average increase of calcium scores was
Goh et al. Cardiovascular Ultrasound 2010, 8:5
http://www.cardiovascularultrasound.com/content/8/1/5
Page 4 of 11
Table 2 (Comparison of Progressors and Regressors in Calcium Scores)
PARAMETERS Patients showing Progression of Calcium score Patients showing Regression of Calcium score
Age as a risk factor 53/70 subjects (= 75.7%) 19/23 subjects (= 82.6%)
Positive Family History 28/70 subjects (= 40%) 10/23 subjects (= 43.5%)
Hypertension 37/70 subjects (= 52.9%) 13/23 subjects (= 56.5%)
Low HDL 23/70 subjects (= 32.9%) 9/23 subjects (= 39.1%)
Smoking 16/70 subjects (= 22.9%) 2/23 subjects (= 8.7%)
Diabetes mellitus 17/70 subjects (= 24.3%) 6/23 subjects (= 26.1%)
Unhealthy Diet 63/70 subjects (= 90%) 19/23 subjects(= 82.6%)
Lack of Exercise 13/70 subjects (= 18.6%) 8/23 subjects (= 34.8%)
Mental Stress 15/70 subjects (= 21.4%) 5/23 subjects (= 21.7%)
Lipid Lowering Treatment
(Maximum Daily Dosage)
Atorvastatin 120 mg Atorvastatin 180 mg
Simvastatin 40 mg Simvastatin 60 mg
Lovastatin 120 mg Lovastatin 80 mg
Pravastatin 40 mg Pravastatin 40 mg
Fluvastatin 20 mg Fluvastatin Absent
Gemfibrozil 1,800 mg Gemfibrozil 900 mg
Fenofibrate 300 mg Fenofibrate Absent
Nicotinic Acid 200 mg Nicotinic Acid Absent
Benfluorex 450 mg Benfluorex 900 mg
Omega-3 Absent Omega-3 tab 1
Sibutramine Absent Sibutramine 10 mg
Cholestyramine 4 grams Cholestyramine 8 grams
Ezetimibe 10 mg Ezetimibe 10 mg
Other Medications AB (Alpha Blockers) AB Absent
ACEI (ACE Inhibitors) ACEI (ACE Inhibitors)
AMIO (Amiodarone) AMIO Absent
APR (Allopurinol) APR (Allopurinol)
ARB (Angiotensin Receptor Blocker) ARB (Angiotensin Receptor Blocker)
ASP (Aspirn) ASP (Aspirn)
AZL Absent AZL (Alprazolam)
BB (Beta Blockers) BB (Beta Blockers)
CCB (Ca. Channel Blockers) CCB (Ca. Channel Blockers)
CLP (Clopidogrel) CLP (Clopidogrel)
DIG (Digoxin) DIG Absent
DR (Diuretics) DR (Diuretics)
GTN Absent GTN (Glyceryl Trinitrate)
INS (Insulin) INS Absent
ISD (Isosorbide Dinitrate) ISD Absent
ISM (Isosorbide Mononitrate) ISM (Isosorbide Mononitrate)
OH (Oral Hypoglycaemics) OH (Oral Hypoglycaemics)
POE (Plant Oestrogens) POE (Plant Oestrogens)
PPF Absent PPF (Propafenone)
T3 (Triiodothyronine) T3 Absent
T4 (Thyroxine) T4 (Thyroxine)
TM (Trimetazidine) TM (Trimetazidine)
WAR (Warfarin) WAR Absent
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24%/year for 52 patients on Statin treatment alone. This
contrasted with 16.4%/year for another 18 patients who
were confirmed by individual specific questioning to
have maintained stringent life-style modification (includ-
ing a strict diet, smoking cessation and stress reduction
(if applicable), regular exercise, weight control) plus
aggressive statin administration, as opposed to an aver-
age of 33.2%/year for untreated patients (p < 0.001) in a
previously published series [7].
Non-progression of CAC scores
A) Patients starting with a baseline score of Zero
A total of 20 patients had a baseline calcium score of 0
(i.e. absence of detectable Calcium). Of these 20
patients, one group of 7 patients started with a zero
score and remained at zero on serial scanning despite
being on no lipid-lowering therapy.
Another group of 13 of these 20 patients also
remained at a zero score, but were on treatment because
of meeting criteria for drug therapy according to ATP
guidelines. 8 of these 13 patients were on statin treat-
ment alone, while another 5 subjects maintained their
zero score by statin therapy plus life-style modification.
Yet another group of 14 patients started with a zero
score but subsequently developed positive calcium
scores on serial scanning.
B) Patients Starting with a baseline Positive Score Showing
a Decreasing Trend
Another group of 23 patients with an initially positive
calcium score had progressive improvement, with a con-
tinual reduction in calcium score values. Such a
REDUCING TREND was observed in patients on stand-
alone statin therapy (for 18 patients) or on life-style
modification plus statins (for 5 patients) [Figure 3].
Overall, 20.4% of the 113 cases demonstrated regression
in their calcium scores.
The number of patients who manifested regression in
calcium score was 23 in all. This small group of patients
was nevertheless unique in the respect of being able to
develop a progressively reducing calcium score. Their
characteristics as compared to patients who progressed
in calcium score are outlined in Table 2. As can be
seen, they do not display any peculiar features as com-
pared with the other subjects in the study, and the rea-
sons for their regression are therefore not apparent.
Detailed Outcomes Of 113 subjects, 96 (85%) stayed on
statins over their entire follow-up period, and main-
tained their cholesterol treatment goals throughout. 91
out of the 113 subjects (i.e. 80.5%) adopted a healthy
diet and 90 out of the 113 subjects (= 79.6%) avoided
smoking, while 81 out of 113 (i.e. 71.7%) engaged in
regular exercise, and 70 out of 113 patients (i.e. 61.9%)
reduced life stress. Although these individuals adapted
to various life-style modifications, at the end of the
study only 31 (i.e. 27.4%) persevered with these changes
throughout their follow-up period.
Adverse events, over 12 years of follow-up included 2
strokes, 1 percutaneous coronary intervention and 2
deaths (1 from cancer, and 1 from suicide).
Possible Pointers to means of achieving differential
outcomes Analysis of patients who progressed versus
those who regressed in calcified plaque burden did not
reveal any specific characteristic trend in terms of age,
sex, risk factor profile (except possibly for smoking) or
degree of lipid-lowering.
Similarly, amongst those subjects who responded with
a retarded rate of rise of calcified plaque on treatment,
there was no clear-cut mechanism for this diminution
in progression, as analysis of the serial lipid profiles of
these patients revealed that Risk Factor Modification did
not improve lipid profile as a means of achieving a
lower annual rise in calcium score [Table 5].
Furthermore, response to therapy was not related to
the type of statins, but dosing was probably important
Table 3 Patient Characteristics at study entry
Number of Patients Age Range Mean Age Calcium Score Range Mean Calcium Score
Male 64 28 - 83 54.4 0 - 2827.1 1413.6
Female 49 36 - 86 62.4 0 - 4586.6 2293.3
Entire Field 113 28 - 86 57.9 0 - 4586.6 2293.3
(Demographics and Range of Calcium Scores of the entire study group)
Table 4 Calcium Scores according to Age
Age Men Mean Score Women Mean Score
20 - 29 0 - 1 0.5 0 0
30 - 39 0 - 489.5 244.75 0 0
40 - 49 0 - 1774.3 887.2 0 - 5.5 2.8
50 - 59 0 - 657 328.5 0 - 195 97.5
60 - 69 0 - 1715.8 857.9 0 - 587.3 293.7
70 - 79 0 - 1612.5 806.3 0 - 849.7 424.9
80 - 89 967.8 - 2827.1 1897.5 0.52 - 4586.6 2293
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since adherence to treatment goals to keep to current N.
C.E.P. guidelines meant statin dosage had to be adjusted
upwards to maintain satisfactory lipid levels as stipulated
by the guidelines in force at the time.
Discussion
The traditional approach to compute coronary risk has
been the application of the Framingham score. However,
it has been found that this scoring system may overesti-
mate the actual risk for various populations outside the
United States [23-28]. Accordingly, refinement of the
actual risk has been proposed by use of various scoring
techniques that apply to individual population groups.
An even simpler, and possibly more accurate, means of
stratifying risk is to directly visualize the coronary
arteries for the presence of atheromatous plaques [29].
Cardiac CT has been used to non-invasively track
changes of coronary atherosclerosis by periodically
quantifying Coronary Artery Calcium (CAC) [30] and
thereby demonstrating the effects of therapy on this
process. Several studies have been conducted to evaluate
the progression of CAC over time. Janowitz et al. [30],
demonstrated that the score progression was more
marked in patients with obstructive CAD compared
with patients who had no clinically manifest disease
(48% versus 27% during the mean 406 days of follow-
up). One study, (n = 81), demonstrated an increase in
the CAC score by 24% each year since baseline [31]
with no specific morbidity/mortality mentioned. Mitch-
ell et al. [32], followed 347 patients for 1.4 years,
demonstrating an annual average increase in CAC
scores of 21% in men and 18% in women. A small study
of young patients with end-stage renal disease demon-
strated a mean calcium score rise of 59% per year, with
a doubling of score by 20 months [33].
Of the 113 patients we studied, all maintained their
intake of statins and a number of them persevered with
life-style changes. We were thus able to observe the
temporal development of these risk factor-bearing symp-
tomatic CAD cases on aggressive non-invasive therapy
over a decade or more of follow-up. Increased adher-
ence has been demonstrated with patients who had
visualization of their CAC [34]. This may have explained
the long term maintenance of therapies.
We demonstrated that the rate of change of CAC, as a
surrogate for coronary atherosclerosis, is 16.4 to 24% per
annum for a variety of underlying risk factors. The rate of
change in the CAC score was slowed by the utilization of
statin therapy for hypercholesterolemia, and 20.4% of parti-
cipants actually exhibited outright regression in this cohort.
Accurate and non-invasive measures of atherosclerosis in
high-risk persons can better assess processes associated
with disease progression, as well as evaluating therapies
that dually prevent the progression or even induce regres-
sion of atherosclerosis/clinical CAD [35]. For this purpose,
a tool is needed to assess efficacy of different interventions
over relatively short time periods. Cardiac CT as a non-
invasive method to measure the quantity of calcified coron-
ary plaque, and capable of measuring rates of change over
time, appeared to fulfill this role in this study.
Furthermore, cardiac CT scanning, being a non-inva-
sive modality, proved to be a convenient means to
Figure 2 This figure is typical of the Rate of Progression of Calcium Scores on Statin Usage. Statins produced a retarded Rising Trend in
Calcium Scores compared to historical untreated Subjects. Ca = Calcium; Pt. = Patient
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quantify disease. By displaying a visual image that was
understandable to patients it presented their condition
in a way to which they could relate. This made it easier
for them to keep up with their treatment and apparently
motivated them to return for follow-up [34].
The findings of Achenbach et al. [36] indicated that
reduction of LDL cholesterol to appropriate levels by
efficacious statin therapy can significantly reduce coron-
ary artery calcium progression, and the results of the
COURAGE Trial [37] further confirmed that optimal
medical therapy can be as effective as percutaneous cor-
onary intervention in stable CAD. In this study, we were
able also to observe the relative contribution of life-style
adjustments versus drug therapy in terms of efficacy in
plaque regression. In this regard, risk factor modification
was found to complement lipid-lowering medications to
produce a slower rise in calcium scores.
In the end, accomplishment of regression may depend
on both long-term lowering of LDL cholesterol (which
prevents new deposits) and allowance of long-term
exposure to the effects of HDL cholesterol (to remove
plaques). Perhaps the answer depends on having a pro-
longed period of time to permit these processes to per-
form their action to the full.
Regarding the low incidence of adverse events in the
group under study, this is understandable from the non-
significant nature of the coronary disease affecting the
whole study group. However it was only after the results
of the study were analyzed that it became possible to be
certain that relative lack of cardiac events can indeed be
achievable by efficacious lipid-lowering therapy. In addi-
tion, the validity of such event-free development needed
to be verified, and was double-checked by tracking
patients’ progress through clinical follow-up and
Figure 3 This figure is typical of the Rate of Regression of Calcium Scores on Statin usage plus Risk Factor Modification. Statins plus
Life-style Modification regressed Coronary Plaques in some cases.
Goh et al. Cardiovascular Ultrasound 2010, 8:5
http://www.cardiovascularultrasound.com/content/8/1/5
Page 8 of 11
telephone interviews. All individual results were further
cross-checked by looking up death certificates held by
the government registry.
A word of caution should be addressed to the direct
evidence from epidemiologic studies that the organ
doses corresponding to a common CT study (two or
three scans, resulting in a dose in the range of 30 to
90 mSv) result in an increased risk of cancer [38].
Although the individual risk estimates are small, the
concern about the risks from CT is related to the
rapid increase in its use. On the basis of such risk esti-
mates and data on CT use from 1991 through 1996, it
has been estimated that 0.4% or more of all cancers in
the United States may be attributable to the radiation
from CT studies. A problem particularly arises for
non-essential CT scans such as repeat scans ordered as
the patient passes through the medical system, often
simply because of a lack of communication. Thus CT
scanning for documentation of CAD should be utilized
only when indicated and targeted to achieving optimal
management of cases with this problem. However, it
should be stressed that in our study, the total dose of
radiation from the electron beam CT scan, over a per-
iod of up to a decade, was well <3-5 mSv for any of
the participants.
Limitations of this study
There was no untreated control group for direct com-
parison in our study, and we therefore relied on the
natural progression of calcium scores in other reported
series for comparison.
The difficulties encountered in the follow-up of cases
included firstly the inherent inter-scan variability of the
calcium score, with possible confounding by varying
treatment protocols due to changing ATP guidelines
over the study period. Furthermore, knowledge of serial
calcium score levels may have influenced the choice or
aggressiveness of the treatment plan.
Conclusions
Excluding cases with critical CAD (who were treated by
revascularization and therefore did not form part of the
cohort under investigation), this decade-long study of
aggressive medical therapy in symptomatic CAD cases
revealed that coronary plaques can be conveniently
detected and followed by serial cardiac CT calcium
scores. It confirmed our hypothesis that serial coronary
calcium scanning can contribute towards disease docu-
mentation in a broad population, in addition to guiding
decisions in patient management. Compared with an
historical 33% rate of increase for untreated subjects,
efficacious statin dosing aided by meaningful life-style
modification in our study allowed 61.9% of cases to dis-
play a reduced rate of progression of calcified plaques
(24% per year for the entire study population, contrast-
ing with 16.4% per year on strict risk factor modification
plus statin therapy), and a further 20.4% demonstrated
actual regression of plaque burden as well. In addition,
Table 5 (Comparison of influence of therapy on the 3 categories of patients)
PARAMETER Patients untreated for
Hypercholesterolaemia
Patients on Statins alone Patients on Statins + Risk Factor
Modification (RFM)
Change in Total
Cholesterol after
intervention
Nil Nil Nil
Change in HDL
Cholesterol after
intervention
Nil Nil Nil
Change in LDL
Cholesterol after
intervention
Nil Nil Nil
Change in
Triglycerides after
intervention
Nil Nil Nil
Change in Calcium
score with
intervention
Nil 52/70 patients (= 74.3%) progressed in Calcium
score on Statins alone
18/23 patients (= 78.3%) regressed in Calcium
score on Statins
18/70 patients (= 25.7%) progressed in calcium
score on Statins + RFM
5/23 patients (= 21.7%) regressed in calcium
score on Statins + RFM
PARAMETERS Patients untreated for
Hypercholesterolaemia
Rising Ca score on
statins alone
Decreasing Ca score on
statins alone
Rising Ca score on
statins + RFM
Decreasing Ca score
on statins + RFM
No. of Patients 7 52 out of 70 patients
(= 74.3%)
18 out of 23 patients
(= 78.3%)
18 out of 70 patients
(= 25.7%)
5 out of 23 patients
(= 21.7%)
Calcium score Zero at baseline and
zero on follow-up
From a mean calcium
score of 111.7 to 301.2
(+169.7%)
From a mean calcium
score of 276.2 to 194.9
(-29.4%)
From a mean calcium
score of 89.17 to 147.6
(+65.5%)
From a mean calcium
score of 26.7 to 19.5
(-27%)
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the rate of adverse events was extremely low (affecting
only 4.4% of the study group) during the more than a
decade of follow-up.
The encouraging results of this study are not only
gratifying to the study subjects but also supported the
findings of the COURAGE TRIAL, which should
accordingly offer added confidence to physicians in
adopting a non-invasive strategy as a viable option for
managing CAD in properly selected patients.
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